Servizio di Immunoematologia e Medicina Trasfusionale,Ospedale S. Giovanni di Dio, ASL n degrees 5, Crotone, Italy.
Blood Transfus. 2007 Jan;5(1):20-3. doi: 10.2450/2007.0010-06.
Phlebotomy is the most commonly treatment used for erythrocytosis and polycythaemia. After the introduction in the medical practice of cell separators, erythrocytapheresis has been also introduced. The aim of the study was to compare the clinical results of the two kinds of treatment.
We analysed 98 patients affected by different forms of erythrocytosis, divided into three treatment groups: 1) patients undergoing phlebotomy; 2) patients treated only with therapeutic erythrocytapheresis; 3) patients who underwent phlebotomy treatment for a certain period and who were then switched to apheresis treatment. The haematocrit in these patients was maintained at about 45% and they were treated when the haematocrit exceeded the critical threshold of 50%.
The interval between two therapeutic interventions was assumed as indicator. In 80% of the patients treated only with phlebotomy the interval was between 20 days and 2 months, in subjects treated with only erythrocytapheresis the intevals were between 2 and 7 months. In the third group of patients, the switch from phlebotomy to erythrocytapheresis considerably prolonged the interval.
The data showed that erythrocytapheresis was clearly superior to traditional phlebotomy in terms of prolonging the period between one treatment and another, independently of the type of erythrocytosis and of the treatment group.
放血疗法是治疗红细胞增多症和红细胞增多症最常用的方法。在细胞分离机引入医学实践后，红细胞分离术也被引入。本研究的目的是比较两种治疗方法的临床结果。
我们分析了 98 例不同形式红细胞增多症患者，将他们分为三组治疗：1）接受放血治疗的患者；2）仅接受治疗性红细胞分离术治疗的患者；3）接受放血治疗一段时间后转为分离术治疗的患者。这些患者的血细胞比容维持在 45%左右，当血细胞比容超过 50%的临界阈值时就进行治疗。
两次治疗干预之间的间隔被认为是指标。仅接受放血治疗的 80%患者的间隔时间为 20 天至 2 个月，仅接受红细胞分离术治疗的患者间隔时间为 2 至 7 个月。在第三组患者中，从放血治疗切换到红细胞分离术显著延长了间隔时间。
数据显示，红细胞分离术在延长治疗间隔方面明显优于传统的放血疗法，这与红细胞增多症的类型和治疗组无关。
